AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32453168 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve catheters placed parallel to the nerve (Group 2, n=38)
Number of subjects: 78
Study 32453168 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 78
Study 34975041 — intervention group
Group type: EXPERIMENTAL
Intervention: New material radial echoendoscope
Number of subjects: 130
Study 34975041 — intervention group
Group type: COMPARATOR
Intervention: Existing endoscope
Number of subjects: 130
Study 33495919 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesylate (NM) 20 mg
Number of subjects: 441
Study 33495919 — intervention group
Group type: COMPARATOR
Intervention: Non-Nafamostat mesylate (non-NM)
Number of subjects: 441
Study 33495919 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesylate (NM)
Number of subjects: 441
Study 33054259 — intervention group
Group type: EXPERIMENTAL
Intervention: Broiler chickens
Number of subjects: 342
Study 33054259 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-range chickens
Number of subjects: 342
Study 33054259 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular detection
Number of subjects: 342
Study 33054259 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis
Number of subjects: 342
Study 35938913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase before endovascular treatment
Number of subjects: 654
Study 35938913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (alteplase + endovascular treatment)
Number of subjects: 654
Study 35938913 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment only
Number of subjects: 654
Study 33236611 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity trunk control training plus low-intensity conventional stroke rehabilitation (45 min, once a day for 5 days)
Number of subjects: 30
Study 33236611 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity conventional stroke rehabilitation (45 min, once a day for 5 days)
Number of subjects: 30
Study 33823205 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 70
Study 33823205 — intervention group
Group type: COMPARATOR
Intervention: LMA Proseal
Number of subjects: 70
Study 33040755 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol-impregnated caps
Number of subjects: 16
Study 33040755 — intervention group
Group type: COMPARATOR
Intervention: Standard practices (without alcohol-impregnated caps)
Number of subjects: 16
Study 32676897 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical students and residents classification of cases
Number of subjects: 240
Study 32676897 — intervention group
Group type: COMPARATOR
Intervention: Medical students and residents versus medical specialists
Number of subjects: 240
Study 35710447 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral acupuncture or acupressure at P6
Number of subjects: 3500
Study 35710447 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 3500
Study 33397429 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Ivermectin at a single dose of 0.2 mg/kg for outpatient and inpatient groups.
Number of subjects: 120
Study 33397429 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment regimen for mild and moderate COVID-19 plus Ivermectin.
Number of subjects: 120
Study 33397429 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine sulfate at a dose of 400 mg twice a day for the first day and 200 mg twice a day for seven subsequent days for outpatient control group.
Number of subjects: 120
Study 33397429 — intervention group
Group type: COMPARATOR
Intervention: 200/50 mg Lopinavir/Ritonavir twice a day for seven days plus five doses of 44 mcg Interferon beta-1a every other day for inpatient control group.
Number of subjects: 120
Study 33397429 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 120
Study 34088734 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 215
Study 34088734 — intervention group
Group type: COMPARATOR
Intervention: Self-Monitoring of Blood Glucose (SMBG)
Number of subjects: 215
Study 32011447 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine Shen-Qi Hua-Yu formula
Number of subjects: 120
Study 32011447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33833401 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (N = 184)
Number of subjects: 281
Study 33833401 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 97)
Number of subjects: 281
Study 36232282 — intervention group
Group type: EXPERIMENTAL
Intervention: Face‐to‐face teaching with active training
Number of subjects: 142
Study 36232282 — intervention group
Group type: COMPARATOR
Intervention: Non‐face‐to‐face teaching with passive training
Number of subjects: 142
Study 32610058 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional a-tDCS (1 mA, 10-minutes)
Number of subjects: 15
Study 32610058 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional c-tDCS (1 mA, 10-minutes)
Number of subjects: 15
Study 32610058 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-a-tDCS (1 mA, 10-minutes)
Number of subjects: 15
Study 32610058 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-c-tDCS (1 mA, 10-minutes)
Number of subjects: 15
Study 33315003 — intervention group
Group type: EXPERIMENTAL
Intervention: Do-module (systematic self-monitoring of positive affect and activities for 28 days)
Number of subjects: 161
Study 33315003 — intervention group
Group type: EXPERIMENTAL
Intervention: Think-module (systematic self-monitoring of negative affect and thinking patterns for 28 days)
Number of subjects: 161
Study 33315003 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional intervention)
Number of subjects: 161
Study 35382845 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (6 sessions of 45 minutes over 12 weeks)
Number of subjects: 94
Study 33779195 — intervention group
Group type: EXPERIMENTAL
Intervention: Probation
Number of subjects: 347
Study 33779195 — intervention group
Group type: COMPARATOR
Intervention: Prison
Number of subjects: 347
Study 33779195 — intervention group
Group type: EXPERIMENTAL
Intervention: Retribution justification
Number of subjects: 347
Study 32432914 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-heat acclimation (EHA) protocol for 8 days, involving 120 min of exercise at 5 km/h, 2% incline, 40°C and 40% relative humidity (RH).
Number of subjects: 13
Study 33085021 — intervention group
Group type: EXPERIMENTAL
Intervention: Annular closure device (ACD) group (276 patients)
Number of subjects: 554
Study 33085021 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) (278 patients)
Number of subjects: 554
Study 33085021 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 554
Study 33085021 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 554
Study 32759183 — intervention group
Group type: EXPERIMENTAL
Intervention: binimetinib
Number of subjects: 0
Study 32759183 — intervention group
Group type: COMPARATOR
Intervention: physician choice chemotherapy
Number of subjects: 0
Study 32759183 — intervention group
Group type: EXPERIMENTAL
Intervention: trametinib
Number of subjects: 0
Study 35108791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg for 7 days
Number of subjects: 137
Study 35108791 — intervention group
Group type: COMPARATOR
Intervention: Not given tamsulosin
Number of subjects: 137
Study 33529593 — intervention group
Group type: EXPERIMENTAL
Intervention: DRSS-guided management
Number of subjects: 40
Study 33529593 — intervention group
Group type: COMPARATOR
Intervention: PLI-guided management
Number of subjects: 40
Study 32088664 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow breathing exercise (daily training for 8 weeks)
Number of subjects: 75
Study 35365371 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite (200 μg/day)
Number of subjects: 60
Study 35365371 — intervention group
Group type: EXPERIMENTAL
Intervention: Se-enriched yeast (200 μg/day)
Number of subjects: 60
Study 35365371 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite and Se-enriched yeast
Number of subjects: 60
Study 35365371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34398955 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF/FTC+DTG
Number of subjects: 385
Study 34398955 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC+DTG
Number of subjects: 385
Study 34398955 — intervention group
Group type: COMPARATOR
Intervention: TDF/FTC/EFV
Number of subjects: 385
Study 35822881 — intervention group
Group type: EXPERIMENTAL
Intervention: WARM (n=10): 2 hours cycling at 50W in 34.4°C water
Number of subjects: 20
Study 35822881 — intervention group
Group type: EXPERIMENTAL
Intervention: HOT (n=10): 1 hour cycling against minimal resistance in 36.7°C water
Number of subjects: 20
Study 33443719 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplement (Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07)
Number of subjects: 0
Study 33443719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32554653 — intervention group
Group type: EXPERIMENTAL
Intervention: MULTIPAP intervention (GPs e-training and GP-patient-centred interview)
Number of subjects: 593
Study 32554653 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 593
Study 35618326 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote home-based exercise programme monitored by phone calls
Number of subjects: 44
Study 35618326 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face home-based exercise programme monitored by home visits
Number of subjects: 44
Study 32732334 — intervention group
Group type: EXPERIMENTAL
Intervention: EarlyCDT‐Lung test plus low‐dose CT scanning 6‐monthly for up to 2 years
Number of subjects: 12208
Study 32732334 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care (control arm)
Number of subjects: 12208
Study 32732334 — intervention group
Group type: EXPERIMENTAL
Intervention: EarlyCDT‐Lung test plus CT screening
Number of subjects: 12208
Study 32270635 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiletto needle combined with massotherapy
Number of subjects: 156
Study 32270635 — intervention group
Group type: COMPARATOR
Intervention: Articular injection of sodium hyaluronate
Number of subjects: 156
Study 35715871 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitated syringe (siliconized or silicone oil-free)
Number of subjects: 41
Study 35715871 — intervention group
Group type: COMPARATOR
Intervention: No agitation (control group)
Number of subjects: 41
Study 35715871 — intervention group
Group type: EXPERIMENTAL
Intervention: Siliconized syringe
Number of subjects: 41
Study 35715871 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil-free syringe
Number of subjects: 41
Study 32635765 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendship with a migraineur
Number of subjects: 610
Study 32635765 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network clustering of migraineurs
Number of subjects: 610
Study 35122096 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month multimodal intervention based on diet and a physical activity program
Number of subjects: 305
Study 35122096 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 305
Study 32860791 — intervention group
Group type: EXPERIMENTAL
Intervention: aFMT (autologous fecal microbiota transplantation)
Number of subjects: 90
Study 32860791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 34870388 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT-low volume (n = 29), 6 intervals of 1-minute high-intensity phases at 90% VO2peak
Number of subjects: 60
Study 34870388 — intervention group
Group type: COMPARATOR
Intervention: MICT (n = 31), trained at 60% VO2peak for 30 minutes
Number of subjects: 60
Study 35590011 — intervention group
Group type: EXPERIMENTAL
Intervention: iRARC with ileal conduit
Number of subjects: 50
Study 35590011 — intervention group
Group type: COMPARATOR
Intervention: ORC with ileal conduit
Number of subjects: 50
Study 33449816 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI/MTX plus abatacept
Number of subjects: 185
Study 33449816 — intervention group
Group type: COMPARATOR
Intervention: CNI/MTX plus placebo
Number of subjects: 185
Study 33449816 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI/MTX plus abatacept (7/8 cohort)
Number of subjects: 185
Study 33449816 — intervention group
Group type: COMPARATOR
Intervention: CNI/MTX (nonrandomized matched cohort)
Number of subjects: 185
Study 34727277 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment group (400 mg celecoxib at 4 h before THA, 200 mg at 4 h after THA, then 200 mg every 12 h until 72 h post-operation)
Number of subjects: 192
Study 34727277 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment group
Number of subjects: 192
Study 34727277 — intervention group
Group type: COMPARATOR
Intervention: Post-treatment group
Number of subjects: 192
Study 32436913 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer etching time, total-etch adhesive system, and EDTA pre-treatment of sclerotic dentin in cervical wedge-shaped defects
Number of subjects: 0
Study 33217117 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg bid)
Number of subjects: 30
Study 33217117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 36088479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripasudil
Number of subjects: 16
Study 36088479 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 16
Study 33595848 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber dam (group 1)
Number of subjects: 20
Study 33595848 — intervention group
Group type: COMPARATOR
Intervention: Retraction cord with copy abutment (group 2)
Number of subjects: 20
Study 32928123 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran arabinoxylan oligosaccharides (AXOS) supplementation
Number of subjects: 21
Study 32928123 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin supplementation
Number of subjects: 21
Study 33097481 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation programme
Number of subjects: 80
Study 33097481 — intervention group
Group type: COMPARATOR
Intervention: Control group (no early mobilisation programme)
Number of subjects: 80
Study 34163144 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital evidence-based patient decision aid (EbPDA) for hypertension
Number of subjects: 124
Study 34163144 — intervention group
Group type: COMPARATOR
Intervention: Control group (searching for information without support)
Number of subjects: 124
Study 36280012 — intervention group
Group type: EXPERIMENTAL
Intervention: PMBE (1322 mg PMBE)
Number of subjects: 62
Study 36280012 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg PMBE)
Number of subjects: 62
Study 36146919 — intervention group
Group type: EXPERIMENTAL
Intervention: Double portion of food (e.g., double portion of banana, carrot, loaf cake, salami)
Number of subjects: 89
Study 36146919 — intervention group
Group type: EXPERIMENTAL
Intervention: Double portion of food
Number of subjects: 89
Study 36146919 — intervention group
Group type: COMPARATOR
Intervention: Reference portion of food (e.g., half a banana, half a large peeled carrot, a slice of loaf cake, half a salami stick)
Number of subjects: 89
Study 32822362 — intervention group
Group type: COMPARATOR
Intervention: Seasonal malaria chemoprevention (SMC) plus placebo
Number of subjects: 10000
Study 32822362 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC within the past 28 days
Number of subjects: 10000
Study 32822362 — intervention group
Group type: COMPARATOR
Intervention: Children who missed the SMC course preceding the survey contact
Number of subjects: 10000
Study 32822362 — intervention group
Group type: EXPERIMENTAL
Intervention: SP + AQ regimen in children with asymptomatic malaria
Number of subjects: 10000
Study 35313852 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Healthy Eating Index (HEI)
Number of subjects: 1738
Study 35313852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy Body Mass Index (BMI) and HEI interaction
Number of subjects: 1738
Study 35313852 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy % from protein and intake of average portions of vegetables and cereals
Number of subjects: 1738
Study 35313852 — intervention group
Group type: COMPARATOR
Intervention: Low Physical Activity (PA) levels
Number of subjects: 1738
Study 35313852 — intervention group
Group type: COMPARATOR
Intervention: Antenatal anxiety/distress
Number of subjects: 1738
Study 35313852 — intervention group
Group type: COMPARATOR
Intervention: Different types of PA
Number of subjects: 1738
Study 33938674 — intervention group
Group type: EXPERIMENTAL
Intervention: US guided SGB with 5 mL of 0.5% bupivacaine and multimodal systemic analgesia (Group A)
Number of subjects: 80
Study 33938674 — intervention group
Group type: COMPARATOR
Intervention: Multimodal systemic analgesia only (Group B)
Number of subjects: 80
Study 33239306 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) in the ESCAPE-NA1 trial
Number of subjects: 111
Study 33239306 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) in the DAWN trial
Number of subjects: 111
Study 33239306 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) in the DEFUSE-3 trial
Number of subjects: 111
Study 70634317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell treatment (all groups pooled)
Number of subjects: 228
Study 70634317 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline wound area
Number of subjects: 228
Study 70634317 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline bacterial counts (>10,000 cfu/gm)
Number of subjects: 228
Study 70634317 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 228
Study 70634317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell treated group
Number of subjects: 228
Study 70634317 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically evident wound infection
Number of subjects: 228
Study 35156955 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual coaching sessions (9 hours over 4-6 months)
Number of subjects: 176
Study 35156955 — intervention group
Group type: COMPARATOR
Intervention: General coaching information (fortnightly)
Number of subjects: 176
Study 35156955 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual coaching sessions
Number of subjects: 176
Study 32394496 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management program
Number of subjects: 49
Study 33295981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower PEEP (0-5 cm H2O), n=476
Number of subjects: 980
Study 33295981 — intervention group
Group type: COMPARATOR
Intervention: Higher PEEP (8 cm H2O), n=493
Number of subjects: 980
Study 33295981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower PEEP
Number of subjects: 980
Study 33295981 — intervention group
Group type: COMPARATOR
Intervention: Higher PEEP
Number of subjects: 980
Study 36174779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle interventions (ILI)
Number of subjects: 4640
Study 36174779 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 4640
Study 34142392 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil extract (500 mg per day for 8 weeks)
Number of subjects: 43
Study 32938280 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 hours of hypothermia
Number of subjects: 92
Study 32938280 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 hours of hypothermia
Number of subjects: 92
Study 32938280 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 92
Study 32938280 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study 35315012 — intervention group
Group type: EXPERIMENTAL
Intervention: Contained collection bag for power morcellation
Number of subjects: 20
Study 35315012 — intervention group
Group type: COMPARATOR
Intervention: Open power morcellation
Number of subjects: 20
Study 34544429 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app education + routine care
Number of subjects: 40
Study 34544429 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 40
Study 36127630 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein point-of-care testing and educational training
Number of subjects: 2039
Study 36127630 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 2039
Study 32956964 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning through Play Plus Thinking Healthy Program (LTP Plus)
Number of subjects: 107
Study 32956964 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 107
Study 32591464 — intervention group
Group type: EXPERIMENTAL
Intervention: GVAX and ipilimumab (Arm A)
Number of subjects: 82
Study 32591464 — intervention group
Group type: COMPARATOR
Intervention: Continuation of FOLFIRINOX (Arm B)
Number of subjects: 82
Study 36268946 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg) and articaine (68 mg) mixture
Number of subjects: 60
Study 36268946 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study 36268946 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 33596969 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical combination of clonidine and pentoxifylline
Number of subjects: 32
Study 33596969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 32521472 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise on a cylinder-shaped tube
Number of subjects: 30
Study 32521472 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise on a flat surface
Number of subjects: 30
Study 32521472 — intervention group
Group type: COMPARATOR
Intervention: Control group (laid supine on a flat surface)
Number of subjects: 30
Study 34274494 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 treatments (specific treatments not detailed)
Number of subjects: 0
Study 35844438 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS plus integrated traditional Chinese and Western medicine
Number of subjects: 74